You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDelavirdine
Accession NumberDB00705  (APRD00149, DB08563)
TypeSmall Molecule
GroupsApproved
Description

A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. [PubChem]

Structure
Thumb
Synonyms
(N-[2-[4-[3-(1-Methylethylamino)pyridin-2-yl]piperazin-1-yl]carbonyl-1H-indol-5-yl] methanesulfonamide)
1-(3-((1-Methylethyl)amino)-2-pyridinyl)-4-((5-((methylsulfonyl)amino)-1H-indol-2-yl)carbonyl)piperazine
2-(4-(5-Methanesulfonamido-1H-indol-2-ylcarbonyl)-1-piperazinyl)-N-(1-methylethyl)-3-pyridinamine
Delavirdin
Delavirdina
Delavirdine
Delavirdinum
N-(2-(1-(3-(Isopropylamino)pyridin-2-yl)piperazine-4-carbonyl)-1H-indol-5-yl)methanesulfonamide
N-{2-[4-(3-isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide
External Identifiers
  • U 90152 S
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Rescriptortablet200 mg/1oralKAISER FOUNDATION HOSPITALS2011-07-06Not applicableUs
Rescriptortablet100 mgoralViiv Healthcare Ulc1998-07-24Not applicableCanada
Rescriptortablet200 mg/1oralVii V Healthcare Company2012-04-11Not applicableUs
Rescriptortablet200 mg/1oralVii V Healthcare Company2010-10-13Not applicableUs
Rescriptortablet100 mg/1oralVii V Healthcare Company2010-10-13Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Delavirdine mesylate
147221-93-0
Thumb
  • InChI Key: MEPNHSOMXMALDZ-UHFFFAOYSA-N
  • Monoisotopic Mass: 552.182474166
  • Average Mass: 552.667
DBSALT000038
Categories
UNIIDOL5F9JD3E
CAS number136817-59-9
WeightAverage: 456.561
Monoisotopic: 456.194359482
Chemical FormulaC22H28N6O3S
InChI KeyInChIKey=WHBIGIKBNXZKFE-UHFFFAOYSA-N
InChI
InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3
IUPAC Name
N-[2-(4-{3-[(propan-2-yl)amino]pyridin-2-yl}piperazine-1-carbonyl)-1H-indol-5-yl]methanesulfonamide
SMILES
CC(C)NC1=C(N=CC=C1)N1CCN(CC1)C(=O)C1=CC2=C(N1)C=CC(NS(C)(=O)=O)=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinylpiperazines. These are compounds containing a pyridinylpiperazine skeleton, which consists of a pyridine linked (not fused) to a piperazine by a bond by a single bond that is not part of a ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPyridinylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Pyridinylpiperazine
  • Indolecarboxylic acid derivative
  • Indolecarboxamide derivative
  • Sulfanilide
  • Indole or derivatives
  • Indole
  • Dialkylarylamine
  • Pyrrole-2-carboxylic acid or derivatives
  • Pyrrole-2-carboxamide
  • Secondary aliphatic/aromatic amine
  • Aminopyridine
  • Imidolactam
  • Benzenoid
  • Substituted pyrrole
  • Pyridine
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Pyrrole
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Secondary amine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
PharmacodynamicsDelavirdine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Delavirdine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of Delavirdine does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by Delavirdine.
Mechanism of actionDelavirdine binds directly to viral reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by disrupting the enzyme's catalytic site.
Related Articles
AbsorptionRapidly absorbed
Volume of distributionNot Available
Protein binding98%
Metabolism

Hepatic

SubstrateEnzymesProduct
Delavirdine
N-desalkyl delavirdineDetails
Route of eliminationDelavirdine is extensively converted to several inactive metabolites by cytochrome P450 3A (CYP3A). Delavirdine was excreted in the milk of lactating rats at a concentration three to five times that of rat plasma.
Half life5.8 hours
ClearanceNot Available
ToxicityMajor toxicity of delavirdine is rash and should be advised to promptly notify their physician should rash occur. The majority of rashes associated with delavirdine occur within 1 to 3 weeks after initiating treatment with delavirdine. The rash normally resolves in 3 to 14 days and may be treated symptomatically while therapy with delavirdine is continued. Any patient experiencing severe rash or rash accompanied by symptoms such as fever, blistering, oral lesions, conjunctivitis, swelling, muscle or joint aches should discontinue medication and consult a physician.
Affected organisms
  • Human Immunodeficiency Virus
Pathways
PathwayCategorySMPDB ID
Delavirdine Action PathwayDrug actionSMP00738
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.6449
Caco-2 permeable-0.6231
P-glycoprotein substrateSubstrate0.7103
P-glycoprotein inhibitor IInhibitor0.7647
P-glycoprotein inhibitor IINon-inhibitor0.5644
Renal organic cation transporterNon-inhibitor0.7808
CYP450 2C9 substrateNon-substrate0.6717
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6707
CYP450 1A2 substrateNon-inhibitor0.6644
CYP450 2C9 inhibitorInhibitor0.6307
CYP450 2D6 inhibitorNon-inhibitor0.8556
CYP450 2C19 inhibitorNon-inhibitor0.6078
CYP450 3A4 inhibitorNon-inhibitor0.6383
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9308
Ames testNon AMES toxic0.6189
CarcinogenicityNon-carcinogens0.7517
BiodegradationNot ready biodegradable0.9891
Rat acute toxicity2.5840 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7656
hERG inhibition (predictor II)Inhibitor0.6118
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Viiv healthcare co
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg
Tabletoral100 mg/1
Tabletoral200 mg/1
Prices
Unit descriptionCostUnit
Rescriptor 200 mg tablet1.92USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2071529 No2001-03-202010-12-24Canada
CA2184598 No2005-05-032015-03-01Canada
US5563142 No1993-10-082013-10-08Us
US6177101 No1999-06-072019-06-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226-228 °CNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.086 mg/mLALOGPS
logP2.77ALOGPS
logP1.02ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)9.39ChemAxon
pKa (Strongest Basic)6.82ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area110.43 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity126.64 m3·mol-1ChemAxon
Polarizability50.01 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

DrugSyn.org

US5563142
General ReferencesNot Available
External Links
ATC CodesJ05AG02
AHFS Codes
  • 08:18.08.16
PDB EntriesNot Available
FDA labelDownload (645 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
Aluminum hydroxideThe serum concentration of Delavirdine can be decreased when it is combined with Aluminum hydroxide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Delavirdine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Delavirdine.
AstemizoleDelavirdine may increase the arrhythmogenic activities of Astemizole.
AtazanavirThe serum concentration of Delavirdine can be decreased when it is combined with Atazanavir.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Delavirdine.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Delavirdine.
BatimastatThe serum concentration of Delavirdine can be decreased when it is combined with Batimastat.
BexaroteneThe serum concentration of Delavirdine can be decreased when it is combined with Bexarotene.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Delavirdine.
BosentanThe serum concentration of Delavirdine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Delavirdine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Delavirdine.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Delavirdine.
Calcium carbonateThe serum concentration of Delavirdine can be decreased when it is combined with Calcium carbonate.
CarbamazepineThe serum concentration of Delavirdine can be decreased when it is combined with Carbamazepine.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Delavirdine.
CimetidineThe serum concentration of Delavirdine can be decreased when it is combined with Cimetidine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Delavirdine.
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Delavirdine resulting in a loss in efficacy.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Delavirdine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Delavirdine.
DabrafenibThe serum concentration of Delavirdine can be decreased when it is combined with Dabrafenib.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Delavirdine.
DarunavirThe serum concentration of Delavirdine can be decreased when it is combined with Darunavir.
DeferasiroxThe serum concentration of Delavirdine can be decreased when it is combined with Deferasirox.
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Delavirdine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Delavirdine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Delavirdine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Delavirdine.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Delavirdine.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Delavirdine.
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Delavirdine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Delavirdine.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Delavirdine.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Delavirdine.
EsomeprazoleThe serum concentration of Delavirdine can be decreased when it is combined with Esomeprazole.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Delavirdine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Delavirdine.
FamotidineThe serum concentration of Delavirdine can be decreased when it is combined with Famotidine.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Delavirdine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Delavirdine.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Delavirdine.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Delavirdine.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Delavirdine.
FosamprenavirThe serum concentration of Delavirdine can be decreased when it is combined with Fosamprenavir.
FosphenytoinThe serum concentration of Delavirdine can be decreased when it is combined with Fosphenytoin.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Delavirdine.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Delavirdine.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Delavirdine.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Delavirdine resulting in a loss in efficacy.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Delavirdine.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Delavirdine.
IndinavirThe serum concentration of Delavirdine can be decreased when it is combined with Indinavir.
IsoflurophateThe serum concentration of Delavirdine can be decreased when it is combined with Isoflurophate.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Delavirdine.
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Delavirdine.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Delavirdine.
LansoprazoleThe serum concentration of Delavirdine can be decreased when it is combined with Lansoprazole.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Delavirdine.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Delavirdine.
Magnesium hydroxideThe serum concentration of Delavirdine can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Delavirdine can be decreased when it is combined with Magnesium oxide.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Delavirdine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Delavirdine.
MitotaneThe serum concentration of Delavirdine can be decreased when it is combined with Mitotane.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Delavirdine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Delavirdine.
NelfinavirThe serum concentration of Delavirdine can be decreased when it is combined with Nelfinavir.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Delavirdine.
NizatidineThe serum concentration of Delavirdine can be decreased when it is combined with Nizatidine.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Delavirdine.
OmeprazoleThe serum concentration of Delavirdine can be decreased when it is combined with Omeprazole.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Delavirdine.
OxycodoneThe risk or severity of adverse effects can be increased when Delavirdine is combined with Oxycodone.
PantoprazoleThe serum concentration of Delavirdine can be decreased when it is combined with Pantoprazole.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Delavirdine.
PhenytoinThe serum concentration of Delavirdine can be decreased when it is combined with Phenytoin.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Delavirdine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Delavirdine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Delavirdine.
RabeprazoleThe serum concentration of Delavirdine can be decreased when it is combined with Rabeprazole.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Delavirdine.
RanitidineThe serum concentration of Delavirdine can be decreased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Delavirdine.
RifabutinThe metabolism of Delavirdine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Delavirdine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Delavirdine can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Delavirdine.
RitonavirThe serum concentration of Delavirdine can be decreased when it is combined with Ritonavir.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Delavirdine.
SaquinavirThe serum concentration of Delavirdine can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Delavirdine.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Delavirdine.
SiltuximabThe serum concentration of Delavirdine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Delavirdine.
Sodium bicarbonateThe serum concentration of Delavirdine can be decreased when it is combined with Sodium bicarbonate.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Delavirdine.
St. John's WortThe serum concentration of Delavirdine can be decreased when it is combined with St. John's Wort.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Delavirdine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Delavirdine resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Delavirdine.
TerfenadineDelavirdine may increase the arrhythmogenic activities of Terfenadine.
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Delavirdine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Delavirdine.
TipranavirThe serum concentration of Delavirdine can be decreased when it is combined with Tipranavir.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Delavirdine.
TocilizumabThe serum concentration of Delavirdine can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Delavirdine.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Delavirdine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Delavirdine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Delavirdine.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Delavirdine.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Delavirdine.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Delavirdine.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Delavirdine.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna-dna hybrid ribonuclease activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72547
Molecular Weight:
65223.615 Da
References
  1. Geitmann M, Unge T, Danielson UH: Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. J Med Chem. 2006 Apr 20;49(8):2367-74. [PubMed:16610780 ]
  2. Xia Q, Radzio J, Anderson KS, Sluis-Cremer N: Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci. 2007 Aug;16(8):1728-37. [PubMed:17656585 ]
  3. Freimuth WW: Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv Exp Med Biol. 1996;394:279-89. [PubMed:8815692 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA, Wang X: Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther. 1998 Oct;287(1):381-8. [PubMed:9765359 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on June 29, 2016 01:50